The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy

Abroad (travel likely)RecruitingPHASE2

Conditions

Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States
Contact: Study coordinator (James Andrews, MD) · jaandrews@uabmc.edu · (205) 934-1564
Contact: Study coordinator (Hannah E Howell, MS) · heburns@uabmc.edu · 205-996-6552
Contact: Principal Investigator (James Andrews, MD)
Johns Hopkins University, Baltimore, Maryland, United States
Contact: Study coordinator (Lisa Christopher-Stine, MD, MPH) · lchrist4@jhmi.edu · 410-550-6962
Contact: Study coordinator (Grazyna Purwin) · gpurwin1@jhmi.edu
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Contact: Study coordinator (Rohit Aggarwal, MD, MS) · aggarwalr@upmc.edu · 412-624-4141
Contact: Study coordinator (Diane C Koontz) · dik4@pitt.edu
University of Texas Health Science Center at Houston, Houston, Texas, United States
University of Washington, Seattle, Washington, United States

Study leads

James Andrews, MD
Principal Investigator
University of Alabama at Birmingham

View source on ClinicalTrials.gov Contact study team (email)